Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies by Arantza Azpilikueta, Ignacio Melero, Sonia Guedan, Alvaro Teijeira, Lieping Chen, Maria C Ochoa, Maite Alvarez, Jose Luis Perez Gracia, Maria E Rodriguez-Ruiz, Miguel F Sanmamed, Assunta Cirella, Javier Glez-Vaz, Irene Olivera, Iñaki Eguren-Santamaria, Carlos Luri-Rey, Xinxin Nie

Get full text

MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers by Pedro Berraondo, Ignacio Melero, Miguel F Sanmamed, Carlos E De Andrea, María Campos, Iñaki Eguren-Santamaria, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Laura Álvarez-Gigli

Get full text

Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism by Iñaki Eguren-Santamaría, Inmaculada Rodríguez, Claudia Herrero-Martin, Eva Fernández de Piérola, Arantza Azpilikueta, Sandra Sánchez-Gregorio, Elixabet Bolaños, Gabriel Gomis, Paula Molero-Glez, Enrique Chacón, José Ángel Mínguez, Santiago Chiva, Fernando Diez-Caballero, Carlos de Andrea, Álvaro Teijeira, Miguel F. Sanmamed, Ignacio Melero

Get full text

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists by Assunta Cirella, Elixabet Bolaños, Carlos Luri-Rey, Claudia Augusta Di Trani, Irene Olivera, Gabriel Gomis, Javier Glez-Vaz, Beatrice Pinci, Saray Garasa, Sandra Sánchez-Gregorio, Arantza Azpilikueta, Iñaki Eguren-Santamaria, Karmele Valencia, Belén Palencia, Maite Alvarez, Maria C. Ochoa, Álvaro Teijeira, Pedro Berraondo, Ignacio Melero

Get full text